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A B S T R A C T
A novel series of 1,5-diarylpyrrol-3-sulfur derivatives (10–12) was synthesized and characterized by NMR and
mass spectroscopy and x-ray diffraction. The biological activity of these compounds was evaluated in in vitro and
in vivo tests to assess their COX-2 inhibitory activity along with anti-inflammatory and antinociceptive effect.
Results showed that the bioisosteric transformation of previously reported alkoxyethyl ethers (9a-c) into the
corresponding alkyl thioethers (10a-c) still leads to selective and active compounds being the COX-2 inhibitory
activity for most of them in the low nanomolar range. The oxidation products of 10a,b were also investigated
and both couple of sulfoxides (11a,b) and sulfones (12a,b) showed an appreciable COX-2 inhibitory activity.
Molecular modeling studies were performed to investigate the binding mode of the representative compounds
10b, 11b, and 12b into COX-2 enzyme and to explore the potential site of metabolism of 10a and 10b due to the
different in vivo efficacy. Among the developed compounds, compound 10b showed a significant in vivo anti-
inflammatory and antinociceptive activity paving the way to develop novel anti-inflammatory drugs.
1. Introduction
Agents able to selectively inhibit cyclooxygenase-2 (COX-2) are
currently used for an effective treatment of inflammatory diseases such
as rheumatoid arthritis (RA) and osteoarthritis (OA).1,2 Several studies
have recently demonstrated that selective COX-2 inhibitors can also
induce apoptosis in colon, stomach, prostate and breast cancer cell
lines.3–7 Furthermore, selective COX-2 inhibitors offer potential for the
prophylactic prevention of inflammatory neurodegenerative disorders
such as Alzheimer’s disease.8
Due to their satisfactory therapeutic profile, selective COX-2 in-
hibitors represent a step forward when compared to traditional
nonsteroidal anti-inflammatory agent (tNSAIDs) being devoid of gas-
trointestinal adverse effects (gastritis, ulcers, bleeding) typical of this
class of drugs (e.g. acetylsalicylic acid, diclofenac, indomethacin, etc.).9
In fact, manipulation of indomethacin structure (1) (Figure 1) by ap-
plying the “scaffold hopping approach”,10 led to the first selective COX-
2 inhibitory compound DuP 697 (2) as the prototype, based on the
diaryl heterocyclic structure. This compound served as the rationale for
the original concept that a drug endowed with greater selectivity for the
pro-inflammatory inducible COX-2 isozyme, relative to the cytopro-
tective constitutive COX-1 isozyme, would have reduced the incidence
of gastrointestinal bleeding. Subsequent drug discovery programs led to
the clinical development of a new class of anti-inflammatory drugs
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referred to as coxibs, in which vicinal diaryl heterocycles constitute the
major class of selective COX-2 inhibitors such as SC-558 (3), celecoxib
(4), rofecoxib (5), etoricoxib (6), and valdecoxib (7). In this regard, all
the compounds cited above differ from the central heterocyclic core:
celecoxib (4) possesses a central five-membered pyrazole ring, whereas
etoricoxib (6) has a central six-membered pyridine ring.11,12 Another
highly selective COX-2 inhibitor rofecoxib (5), which belongs to the
diaryl heterocylic class possesses a central five-member lactone, [2(5H)
furanone], ring system while valdecoxib (7) is based on an isooxazole
ring.13 Extensive structure–activity relationship (SAR) studies for the
diaryl heterocyclic class have shown that a sulfonamide (SO2NH2) or a
methyl sulfone (SO2Me) and fluoro substituents at the para position of
one of the aryl rings often provides optimum COX-2 selectivity and
potency.14
Unfortunately, it was found that the gastrointestinal benefit of
coxibs is frustrated by the finding of increased incidence of undesirable
cardiovascular side-effects.15 However, according to the evidences of
different observational studies and randomized clinical trials the car-
diovascular hazard is not restricted to selective COX-2 inhibitors but
also to some tNSAIDs, such as diclofenac.16 The most plausible me-
chanism is the suppression of COX-2-dependent prostacyclin, leaving
unconstrained the intricate network of stimuli predisposing to ather-
ogenesis, hypertension, and thrombosis, such as Thromboxane
(TxA2).17 The finding of a marked variability in how each person reacts
to these drugs,18 encouraged the development of novel compounds in
order to increase the spectrum of therapeutic opportunities for each
individual patient.
Thus, more than a decade ago we started a wide research program
focused on the synthesis of 3-substituted-1,5-diarylpyrrole derivatives
(8)19,20 as new selective COX-2 inhibitors in which the pyrroleacetic
and vicinal diaryl heterocyclic moieties were reminiscent of in-
domethacin (1) and of the above “coxib” family, respectively.
Further functionalization of the chain in position 3 of the pyrrole
moiety allowed us to enlarge the library of previously reported com-
pounds (8) with a small series of 1,5-diarylpyrrole-3-alkoxyethyl ethers
(9).21 Among these, the hydroxyethyl derivatives (R=CH2CH2OH in
Figure 1) were disclosed when the research project was extended to the
synthesis of hybrid molecules, essentially new classes of pyrrole-derived
nitrooxyalkyl inverse esters,22 and ethers as COX-2 selective inhibitors/
nitric oxide (NO) donors also referred to as CINOD (Figure 1).23
In the in vitro cell culture assay, all the compounds proved to be
potent and selective COX-2 inhibitors. In the human whole blood
(HWB) assay, compound 9a (X=H, R= n-Pr, see Table 1 for the exact
structure) had a comparable COX-2 selectivity to valdecoxib, while it
was more selective than celecoxib but less selective than rofecoxib. The
potential anti-inflammatory and antinociceptive activities of
Figure 1. From tNSAIDs to coxibs: structures of indomethacin (1), reference compounds (2–7), 1,5-diarylpyrrole-3 substituted derivatives (8, 9) and development of
novel selective COX-2 tio-inhibitors.
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compounds 9a and 9b (X= F, R= n-Pr, see Table 1 for the exact
structure) were evaluated in vivo, where they showed a very good ac-
tivity against both carrageenan-induced hyperalgesia and oedema in
the rat paw test. In the abdominal constriction test compounds 9a and
9b were able to reduce the number of writhes in a statistically sig-
nificant manner.21
Compound 9a was also evaluated to assess its effect on human os-
teoarthritic chondrocytes exposed to Interleukin(IL)-1β showing a
beneficial effect on chondrocytes metabolism.24 In addition, when
tested to evaluate their antiproliferative activity in the HaCaT (aneu-
ploid immortal keratinocytes from adult human skin), compounds 9a
and 9b showed a strong inhibition of cell proliferation and did not
exhibit cytotoxicity.25 The research continued with the synthesis of
different fluorinated 1,5-diarylpyrrole-3-alkoxyethyl ether derivatives
with the aim of investigating the biological effects that could have been
elicited by insertion of a fluorine atom in a different portion of the
previously synthesized COX-2 inhibitors.26 Among them, compound 9d
exhibited a prominent in vivo anti-inflammatory and antinociceptive
activities, also confirming the antiproliferative but not toxic effect on
HaCaT cell of this class of compounds (Figure 1).26 These data sug-
gested that compounds 9a-d along with their role in inhibiting COX-2
and inflammation, could have a possible therapeutic (topical or sys-
temic) use against skin proliferative disorders, such as psoriasis.
As for hydroxyethyl derivative 9e (X= F, R=CH2CH2OH, see
Table 1 for the exact structure), as well as compounds 9a-d, it de-
monstrated an appreciable anti-inflammatory and antinociceptive ac-
tivity in animal models of inflammation and for this reason underwent
biological assays performed on bovine articular cartilage, in which 9e
proved to be endowed with chondroprotective effects being able to
inhibit glycosaminoglycans release induced by IL-1β.23
Very recently, compound 9e was also found to have more beneficial
effect compared with celecoxib with special regard to the modulation of
oxidation/anti-oxidant system and proteasome profile of human ar-
ticular chondrocytes.27
In this work, following the strategy of bioisosterism, a hitherto
unknown series of 1,5-diarylpyrrol-3-sulfur derivatives (10–12) was
synthesized, the biological activity of which was evaluated in in vitro
and in vivo test to assess their inhibitory COX-2 activity along with anti-
inflammatory and antinociceptive effect.
2. Results and discussion
As a third row element sulfur is able to expand its valence shell to
form more than four covalent bonds assuming different oxidation states
ranging from−2 to+6 that allow this atom to assume a variety of
molecular arrangements, making it one of the most chemically versatile
Table 1
Biological activity of target compounds 10–12 in comparison with that of previously reported alkoxyethyl ethers 9a-d, and hydroxyethyl ether 9e.
Cmpd X R IC50 IC50 COX-1/COX-2
COX-1 (µM)a COX-2 (µM)a (SI)b
9ac H n-Pr > 100 0.018 >5555
9bc 4-F n-Pr > 100 0.030 >3333
9cc 3-F n-Pr > 100 0.013 >7692
9dd 4-F (CH2)3F > 100 0.007 >14.285
9ee 4-F (CH2)2OH >10 0.089 >112.3
10a H n-Pr > 10 0.014 >714
10b 4-F n-Pr > 10 0.011 >909
10c 3-F n-Pr > 10 0.285 >24
11a H n-Pr > 10 0.060 >167
11b 4-F n-Pr > 10 0.040 >250
12a H n-Pr > 10 0.034 >294
12b 4-F n-Pr > 10 0.044 >227
Celecoxibd – – 5.1 0.079 65
a Results are expressed as the mean (n= 3 experiments) of the % inhibition of PGE2 production by test compounds with respect to control samples. The IC50
values were calculated by the GraphPad Instat program. Data fit was obtained by means of the sigmoidal dose−response equation (variable slope) (GraphPad
software).
b In vitro COX-2 selectivity index [IC50(COX-1)/IC50(COX-2)].
c See reference [21].
d See reference [26]
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of the early elements.28 Many compounds and marketed drugs endowed
with biological activity include the S-linker comprising sulfide (R-S-R’),
sulfinyl (R-S(O)-R’) and sulfonyl R-(SO2)-R’ groups29 [e.g. montelukast,
esomeprazole, and amisulpiride, respectively]. Therefore, the trans-
formation of previously reported pyrrole 1,5-diarylpyrrole-3-sub-
stituted alkoxyethyl ethers as highly selective COX-2 inhibitors 9a-
c21,26 into the bioisosteric sulfur-containing homologues, could be
conceived as a further functionalization of position 3 of the pyrrole
scaffold. Moreover, operating in this direction, it appeared obvious to
investigate their oxidation products such as alkyl sulfoxides and alkyl
sulfones. In fact, all three species of sulfur derivatives are present in the
pharmacokynetic pathway of well-known drugs like non-steroidal anti-
inflammatory agent (NSAID) sulindac in which the inactive sulfoxide
undergoes either reduction to the active sulfide metabolite or irrever-
sible oxidation to sulindac sulfone,30 differently from the antigout agent
sulfinpyrazone in which the sulfoxide is the active compound while the
sulfide and the sulfone are the inactive metabolites.31
2.1. Chemistry
The synthesis of the designed compounds is reported in Scheme 1.
Initially, the hydroxyethyl derivatives 13a-c were prepared in gram-
scale according to the previously-reported procedure.21 The activation
of the suitable alcohol 13a-c by means of tosyl chloride in the presence
of N,N-diisopropylethylamine (DIPEA) and 4-(dimethylamino)pyridine
(DMAP) gave the corresponding O-tosyl derivatives 14a-c which were
smoothly alkylated by reaction with sodium 1-propanthiolate in di-
methylsulfoxide (DMSO) at room temperature to provide alkyl sulfides
also referred to as thioethers, 10a-c in satisfactory yields.32
Sulfoxides and sulfones are generally prepared by mono or full
oxidation of sulfides and the chemoselectivity of the oxidation depends
on the reaction conditions, amount of oxidizing agent, typically hy-
drogen peroxide and the use of a promoter like triflic anhydride or
molybdenum(VI) oxide.33
Surprisingly, the chemoselective oxidation of sulfides 10a,b to ob-
tain sulfoxides 11a,b and sulfones 12a,b following the above-cited
Scheme 1. Synthesis of the new COX-2 inhibitors 10a-c, 11a,b and, 12a,b. Reagents and conditions: (i) TsCl, DMAP, DIPEA, DCM, r.t., 20 h; (ii) sodium 1-
propanthiolate, dry DMSO, r.t., 1 h; (iii) mCPBA, DCM, 2 h, r.t..
Table 2
Effect of compounds 10a-c, and 11b on hyperalgesia and edema induced by carrageenan in the rat paw-pressure test.a
Pre-treatment i.pl. Treatment p.o. Paw Pressure (g) Paw Volume (mL)
DOSE (mg Kg−1) Before Treatment After Treatment
30min. 60min. 90min. 30min.
Saline CMC – 60.2 ± 2.7 59.3 ± 2.5 62.8 ± 3.3 60.5 ± 4.4 1.59 ± 0.08
Carrageenan CMC – 35.4 ± 3.8 33.9 ± 3.7 37.2 ± 3.5 36.7 ± 4.0 2.78 ± 0.09
Carrageenan 10° 20 36.7 ± 4.7 46.0 ± 4.0^ 40.3 ± 3.5 40.2 ± 3.8 1.69 ± 0.10*
Carrageenan 10b 20 34.8 ± 3.8 57.3 ± 4.2* 50.4 ± 4.0* 41.9 ± 4.0 1.75 ± 0.09*
Carrageenan 10c 20 37.9 ± 4.3 41.5 ± 3.1^ 38.8 ± 3.4 37.2 ± 3.1 1.74 ± 0.07*
Carrageenan 11b 20 35.6 ± 3.9 53.5 ± 4.1* 42.5 ± 3.6 38.2 ± 3.7 1.55 ± 0.07*
a All compounds were administered at the dose of 20mg kg−1 p.o. Carrageenan (100 μL – 1% - i.pl. 2 h before test). Test was performed 30min after the compound
injection. There were 4–5 rats per group. ^P < 0.05 versus the corresponding carrageenan-treated rat; *P < 0.01 versus the corresponding carrageenan-treated rat.
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conditions was unsuccessful obtaining complex reaction mixtures.
Therefore, we decided to selectively oxidize sulfides 10a,b by means of
meta-chloroperoxybenzoic acid (mCPBA) in dry dichloromethane.34 In
this condition, we obtained sulfoxides 11a,b as the main products
(about 60% of yield) and sulfones 12a,b as by-product (about 10% of
yield). Sulfoxides and sulfones were easy separated by flash chroma-
tography, characterized, and used for in vitro and in vivo biological
evaluation.
2.2. In vitro assay
The inhibitory potency and selectivity on both COX-isoforms of the
title compounds was evaluated by in vitro cell culture (J774 murine
macrophage) assay. The results were summarized in Table 1 and
compared with some previously reported analogues alkoxyethyl ether
compounds.
Results showed that the bioisosteric transformation of alkoxyethyl
ethers 9a-c into the corresponding alkyl thioethers (10a-c) still leads to
selective and active compounds being the COX-2 inhibitory activity for
most of them in the low nanomolar range. In particular, no significant
difference between oxygen or sulfur linker were observed comparing 9a
(IC50= 0.018 µM) and 10a (IC50= 0.014 µM). In the same way, ele-
vated COX-2 inhibitory and selective effect was observed when a fluoro
substituent in the para position of the pendant N-1 phenyl ring was
inserted as in 9b (IC50= 0.030 µM) and 10b (IC50= 0.011 µM).
Therefore, in the 3-substituted-1,5-diarylpyrrole series the con-
temporary presence of the propyl sulfide moiety and 4′-fluoro sub-
stituent as in 10b represents the best combination to elicit a potent and
selective COX-2 inhibitory activity. On the contrary, a significant loss of
inhibitory activity on COX-2 was observed transforming compound 9c
into the analogue thioether 10c.
On the basis of the promising inhibitory activity data obtained with
thioether compounds 10a,b, we investigated the inhibitory activity on
both COX isoforms of compounds 11a,b and 12a,b considered as pos-
sible products of metabolic oxidation of the most active thioether de-
rivatives. Both couple of sulfoxides 11a,b and sulfones 12a,b showed
an appreciable COX-2 inhibitory activity with an IC50 between 0.034
and 0.060 µM. These data suggest that even the oxidation products of
propyl sulfides 10a,b retain an intriguing COX-2 inhibitory activity
regardless of the presence of the fluorine atom in para position of the
pendant N-1 phenyl ring.
Intriguingly, sulfoxide 11a,b and sulfones 12a,b show similar na-
nomolar COX-inhibitory activity in the range of the alkoxyethyl ethers
9. This observation suggests that the oxygen atom in the oxidized sulfur
derivatives (at least one in the sulfones) may be involved in productive
interactions analogously to the oxygen atom present in the side chain of
compounds 9, implicated in hydrogen bonds with the guanidine moiety
Table 3
Effect of compounds 10a-c, and 11b in the mouse abdominal constriction test
(acetic acid 0.6%).
Treatmenta n° mice DOSE per os (mg Kg−1) n° writhes
CMC 12 – 30.5 ± 3.7
10a 5 10 32.6 ± 3.9
10a 5 20 25.9 ± 3.2^
10a 5 40 26.4 ± 3.0^
10b 5 10 28.7 ± 4.1
10b 5 20 17.4 ± 2.5*
10b 5 40 15.9 ± 3.6*
10c 5 10 30.3 ± 3.5
10c 5 20 23.4 ± 3.0^
10c 5 40 23.7 ± 3.3^
11b 5 10 28.8 ± 3.3^
11b 5 20 23.4 ± 3.0^
11b 5 40 20.3 ± 3.8^
a All drugs were administered per os 30min before test. ^P < 0.05 vs ve-
hicle-treated mice; *P < 0.05 vs vehicle-treated mice.
Figure 2. Best docked poses of compounds 10b
(panel A; green sticks), 11b (panel B; cyan sticks) and
12b (panel C; magenta sticks) into hCOX-2 (orange
cartoon PDB ID: 5KIR) binding site. The key residues
in the active site were represented by lines. H-bonds
were represented by dark grey dotted lines. The
nonpolar hydrogens were omitted for the sake of
clarity. The picture was generated by means of
PyMOL (The PyMOL Molecular Graphics System,
version 1.8.4.0, Schrödinger, LLC, New York, 2018).
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of R120 and/or Y355 located in hydrophobic environment of the COX-2
“carboxylate binding site”.21
2.3. In vivo anti-inflammatory and antinociceptive studies
On the basis of their interesting COX-2 inhibitory activity observed
in the in vitro test, compounds 10a-c, together with compound 11b
(considered as the oxidation product of the most potent thioether
compound 10b) were selected as candidates for further pharmacolo-
gical test to assess their in vivo anti-inflammatory and antinociceptive
activities by carrying out the carrageenan-induced rat paw test, the paw
volume test and the abdominal constriction test (Tables 2 and 3).
In the first test, the intraplantar administration of carrageenan in
the paw induces all typical inflammatory signs (i.e. paw swelling, hy-
peremia and hyperalgesia). Then, the selected compounds were ad-
ministered at a dose of 20mg/kg p.o. and the effect on the paw pressure
tolerance and the volume of the paw were measured. All compounds
showed a good activity against carrageenan-induced hyperalgesia
30min after administration, disappearing almost completely at 2 h after
treatment (Table 2). In particular, compound 10b and its oxidized re-
lated molecule 11b induced a tolerance higher than 53 g after 30min
from the treatment. However, while 10b continues its significant ac-
tivity even after 60 and 90min, the pain tolerance induced by com-
pound 11b significantly decreases after 60min. Moreover, a very good
activity was demonstrated against carrageenan induced edema in the
rat paw (Table 2), with a substantial complete remission in 1 h after the
administration of all compounds at the same dose of 20mg/kg p.o.
In the abdominal constriction test compounds 10a-c, and 11b were
able to reduce the number of writhes in a statistically significant
manner at the minimum dose of 20mg/kg p.o., while at the dose of
10mg/kg p.o., they were devoid of any antinociceptive efficacy
(Table 3). Among these, a significant decrease of the writhing was
highlighted by compound 10b, in line with its higher potent affinity for
the COX-2 isoform.
2.4. Molecular modeling studies
The aim of this computational study was threefold: a) to investigate
the potential binding modes of such new class of inhibitors within the
COX-2 binding site; b) to assess which, among sulfides 10, sulfoxides
11, and sulfones 12, might be the real active compound or the inactive
metabolite; c) to verify if the presence of S]O, or SO2 functional group
in the alkyl chain of 3-substituted 1,5-diarylpyrrole scaffold may have
additional fruitful interactions within the binding site of COX-2 to
maintain the selective inhibitory activity allowing at the same time to
upgrade the structure–activity relationship (SAR) in this class of com-
pounds and to confirm the bioisosteric suggestion.
In order to elucidate the inhibitor-enzyme interactions a molecular
docking protocol has been used as described previously for alkoxyethyl
ethers 9a-c.21,26 In particular, we were aimed at understanding the
influence of n-propyl chain in the binding modes of the newly con-
ceived COX-2 selective inhibitors. Accordingly, each compound was
docked into human COX-2 (hCOX-2). To this end, Glide software with
XP as scoring function was used for docking procedure along with
hCOX-2 enzyme (PDB ID: 5KIR) and compounds 10b, 11b, and 12b.
Briefly, all the compounds showed a similar accommodation into
hCOX-2 binding site with comparable docking scores. In particular, the
selected compounds showed the following docking scores: for 10b we
observed −7.97 kcal/mol of XPscore, for 11b and 12b the XPscores are
−7.99 kcal/mol, and −7.61 kcal/mol, respectively. The comparable
docking scores support similar potency in inhibiting the COX-2 enzyme
in the low nanomolar range, although compound 10b is the best in-
hibitor with an IC50 of 0.011 µM. Regarding the docking outputs (Figure
2), all the compounds are able to interact with R513 by polar contacts
and with Y355 and F518 by hydrophobic interactions. Moreover,
compound 10b can establish an additional H-bond with the backbone
of F518. Compounds 11b and 12b are not able to form the mentioned
H-bonds due to the H-bonds network established by the side chains of
Y355 and R120. These polar contacts led to a slight movement of the
compounds into the binding site precluding the formation of the H-
bond with the backbone of F518 since the distance is over 3 Å. Inter-
estingly, the n-propyl moiety is well-tolerated by the enzyme observing
its accommodation into a hydrophobic sub-pocket mainly composed by
M113, Y115, V116, Y355, L531, L359. Although, the three compounds
are able to accommodate the aliphatic chain into the mentioned sub-
pocket we noted that the H-bonds formed from compounds 11b and
12b did not allow the n-propyl moiety to strongly interact with the
above mentioned hydrophobic region, due to a different constrained
conformation of this moiety, causing a weak interaction with respect to
compound 10b. This evidence is supported by the estimation of the
Glide energy that provides a modified Coulomb-van der Waals inter-
action energy value taking into account the hydrophobic contribution
to the binding. Compound 10b possesses the most favourable Glide
energy (-18.42 kcal/mol) over compounds 11b and 12b (-12.31 kcal/
mol and −13.04 kcal/mol, respectively). This hydrophobic binding
contribution could support the slight differences in COX-2 inhibition.
2.5. In silico prediction of potential sites of metabolism
Despite the similar potency in COX-2 inhibition observed for com-
pounds 10a and 10b, we noted a different efficacy when the com-
pounds were tested in vivo. In particular, compound 10b showed a
superior anti-inflammatory and antinociceptive profile with respect to
those found for 10a. This different in vivo efficacy could be ascribable to
the different metabolic stability of the compounds. In fact, we specu-
lated that compound 10a could be quickly metabolized contrarily to
compound 10b. This possibility prompted us to computationally in-
vestigate the differences in the sites of metabolism of the above-men-
tioned compounds. It is well established that cytochrome P450 enzymes
are crucial in the metabolism of drugs. These heme-containing enzymes
catalyze several reactions, including dealkylation, hydroxylation and
double-bond oxidation, resulting in the degradation of compounds. The
prediction of the sites of metabolism of drug-like molecules provides an
overview of the metabolic stability of molecules, suggesting potential
modification for the rational design of novel molecules with improved
pharmacological profile. For this purpose we employed P450 site of
metabolism (P450 SOM) application implemented in Schrödinger suite
2011. As demonstrated by some of us, this application is very useful in
predicting potential soft spots aiming at understanding the liable sites
of the molecules.35 In particular, we predicted metabolism-mediated by
isoforms CYP3A4, CYP2C9, and CYP2D6 of 10a and 10b. The predic-
tion for isoforms CYP2C9 and CYP2D6 combined induced-fit docking
(which determines accessibility of the compounds to the CYP reactive
centre) with a rule-based approach to intrinsic reactivity. In the case of
CYP3A4, which has a highly flexible binding site, only intrinsic re-
activity was used to predict soft spots.36,37 The output of this in silico
evaluation was reported in Table 4.
Based on the calculations, we speculate about the possibility that
the mediated-metabolism of the mentioned molecules could be mainly
determined by the isoforms CYP3A4 and CYP2C9 given that the cal-
culation with the isoform CYP2D6 did not produce any results in terms
of docking poses, denoting a lower affinity of these compounds for the
CYP2D6 isoform. Concisely, compound 10a is accommodated into
CYP2C9 projecting the N1-phenyl substituent towards the iron center of
heme group (Figure 3). In particular, the para position of the mentioned
substituent was found to be at only 3.8 Å, representing the main soft
spots of the molecule. Accordingly, in this region relevant modifications
of the molecule mediated by the heme-containing enzymes should
occur.
The other soft spots in the sulfur chain could be less relevant in the
metabolism of the compound 10a since although the distances found
between the potential soft spots in the chain and the reactive center are
A. Reale, et al. Bioorganic & Medicinal Chemistry 27 (2019) 115045
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under 4 Å, the predicted accessibility to the iron reactive center is
dramatically decreased with respect to the N1-phenyl para position. On
the contrary, the presence of the fluorine atom in 10b was predicted to
reduce CYP3A4- and CYP2C9-mediated metabolism leading to more
stable analogues. In fact, as highlighted by the results reported in
Table 4 we can observe a dramatic decrease of the potential soft spots
with a reduction of potential sites of metabolism. Accordingly, 10b
showed a significant decrease of the intrinsic reactivity for CYP3A4,
and no relevant interactions with isoforms CYP2C9, and CYP2D6. The
presented computational analysis supports the different in vivo efficacy
representing one of the main reasons of the different anti-in-
flammatory/antinociceptive profile of the compound 10a with respect
Table 4
Results for prediction of sites of metabolism for studied compounds by P450 site of metabolism (P450 SOM) prediction workflow implemented in Schrödinger suite
2011.
Comp CYP3A4a CYP2C9b CYP2D6b
10a no pose obtainedc
10b no pose obtainedc
a In the structure of each compound, atoms with the accessibility and the intrinsic reactivity for 3A4 are marked by green circles, in which the circle radius is
proportional to the score. Larger scores mean higher reactivity.
b In the structure of each compound, the Fe-accessibility of 2C9 and 2D6 are indicated by a set of green rays drawn out from the atom. The number of rays
indicates the value of the Fe-accessibility, as determined by induced-fit docking. Each full-length ray represents one unit of accessibility, so the number of full-length
rays is the integer part of the score. The remaining partial ray represents the decimal part of the score. The circles represent the overall score and the intrinsic
reactivity. The radius of the circle corresponds to this score. The intensity of the red colour for each circle is proportional to the atomic intrinsic reactivity (the highest
level of intrinsic reactivity was determined by dark red). A blue ring around the circle indicates that the atom passed through the CYP filtering stage. No ring indicates
that the atom failed the CYP filtering stage.
c the P450 SOM procedure did not found any poses into the isoforms and no compound-CYP2D6 complexes were formed.
Figure 3. P450SOM docked pose of compounds 10a (spring green sticks) into
the CYP2C9 binding site (cyan cartoon). The binding site residues are re-
presented by lines, the heme group is represented by light purple stick and the
iron is represented by a grey sphere. The distance between the N1-phenyl para
position and the iron center is shown in red and the distance is expressed in Å.
The picture was generated by PyMOL.
Figure 4. CYP-dependent metabolic depletion of 10 μM 10a (A) and 10b in
human liver microsomal preparations. Results are presented graphically as
percentage of compound recovery (100% at time 0min) as a function of in-
cubation time. Data are presented as mean ± sem, of three different experi-
ments.
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to compound 10b in the presented animal models.
2.6. In vitro metabolic stability of 10a and 10b in human liver microsomes
In order to better explain experimentally the different efficacy in the
in vivo studies and rationalize the computational predictions, the me-
tabolic stability of compound 10a and 10b was assessed in human liver
microsomal preparations. The plot of non-metabolized compound (%)
versus time showed monoexponential decay relationship (Figure 4).
The apparent decay constants k were 0.03245min−1 and 0.0128min−1
for 10a and 10b, respectively. The resulted half-life time and Clint
were, respectively t½ =21.4 and 54.15min and Clint= 58.3 and
22.9 μL/min, for 10a and 10b, respectively.
These results clearly indicate that compound 10a should be con-
sidered moderate substrate of Cytochrome P450 system as resulted
from its intrinsic clearance value. Interestingly the introduction of a
fluorine in the molecule increased its metabolic stability. In fact the
half-life time resulted more the two fold greater in the compound 10b.
The results suggest that both compounds can possessed a favourable
pharmacokinetic property, at least regarding their interaction with
phase I enzyme system.
3. Conclusions
In summary, we have reported the design, synthesis, computational
investigation and the biological evaluation based on in vitro and in vivo
experiments of a novel series of 3-substituted 1,5-diarylpyrrole sulfur
derivatives as COX-2 selective inhibitors endowed with anti-in-
flammatory/antinociceptive profile. In particular, the biological eva-
luation highlighted the strong inhibitory potency against the COX-2
enzyme in the low nanomolar range with no significant affinity against
COX-1 with a remarkable selectivity ratio. Molecular modeling studies
provided a detailed model of interaction into the COX-2 binding site for
understanding the role of the different substituents introduced in lateral
chain of the developed COX-2 selective inhibitors. Moreover, an ex-
tensive in silico investigation of the sites of metabolism of the molecules
together with in vitro metabolic stability studies in human liver mi-
crosomes, allowed to propose one of the main reasons regarding the
different in vivo potency observed for the compounds 10a and 10b.
Overall, among the novel conceived derivatives, compound 10b de-
monstrated the best efficacy in animal models of inflammatory pain
over its congeneric compounds opening the way to the development of
a novel anti-inflammatory and antinociceptive agent.
4. Materials and methods
4.1. Chemistry
All chemicals used were of reagent grade. Yields refer to purified
products and are not optimized. Melting points were determined in
open capillaries on a Gallenkamp apparatus and are uncorrected. Merck
silica gel 60 (230–400 mesh) was used for column chromatography.
Merck TLC plates and silica gel 60 F254 were used for TLC. 1H- and 13C
NMR spectra were recorded with a Bruker AC 400 spectrometer in the
indicated solvent (TMS as internal standard). The values of the che-
mical shifts are expressed in ppm, and the coupling constants (J) are
expressed in Hz. Mass spectra were recorded using an Agilent 1100 LC/
MSD operating with an electrospray source. Purity of compounds 10a-
c, 11a,b, and 12a,b was assessed by RP-HPLC and was found to be
higher than 95%. Merck LiChroCART® 125–4 C18 column was used in
the HPLC analysis with acetonitrile–water-methanol (20:70:10) or
acetonitrile-methanol (80:20) as the mobile phase at a flow rate of
1.0 mL/min. UV detection was achieved at 228 nm.
4.1.1. General procedure for the synthesis of tosylate derivatives 14a-c.
To a solution of the suitable alcohol (13a-c)21,26 (1 equivalent) in
CH2Cl2 (30mL), 4-(dimethylamino)pyridine (DMAP) (1.5 equivalents)
and N,N-diisopropylethylamine (DIPEA) (1.5 equivalents) were added
in sequence. The solution was cooled at 0 °C, and tosyl chloride (1.5
equivalents) was added. After stirring for 3 h at room temperature, the
reaction mixture was treated with water and the organic layer was
washed with water, dried over anhydrous Na2SO4, filtered and evapo-
rated in vacuo. The residue was purified by flash chromatography with
the indicated eluent to obtain the expected tosyl derivative.
4.1.2. 2-(2-Methyl-5-(4-(methylsulfonyl)phenyl)-1-phenyl-1H-pyrrol-3-yl)
ethyl-4-methylbenzene sulfonate (14a).
The title compound was obtained starting from the hydroxyl deri-
vative 13a (1.1 g, 3.28mmol) as a light yellow solid (1.17 g, yield 70%)
using petroleum ether-ethyl acetate (1:1 v/v) as the eluting mixture. 1H
NMR (400MHz, CDCl3) δ ppm: 1.98 (s, 3H), 2.40 (s, 3H), 2.84 (t,
J= 7.2, 2H), 2.98 (s, 3H), 4.18 (t, J= 7.2, 2H), 6.30 (s, 1H), 7.08 (d,
J=8.4, 4H), 7.29 (d, J= 7.6, 2H,), 7.38 (m, 3H), 7.62 (d, J= 8.4, 2H),
7.76 (d, J= 8.0, 2H). MS(ESI): m/z 510 (M+H+).
4.1.3. 2-(1-(3-Fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)-1H-
pyrrol-3-yl)ethyl-4-methyl benzenesulfonate (14b).
The title compound was obtained starting from the hydroxyl deri-
vative 13b (0.74 g, 1.98mmol) as a white solid (0.86 g, yield 82%,
mp=145.5–147.0 °C) using petroleum ether-ethyl acetate (7:3 v/v) as
the eluting mixture. An X-ray quality analytical sample was obtained by
recrystallization from dichloromethane by slow evaporation (Figure 5).
1H NMR (400MHz, CDCl3) δ ppm: 1.98 (s, 3H), 2.41 (s, 3H), 2.84 (t,
J= 7.2, 2H), 3.00 (s, 3H), 4.19 (t, J= 7.2, 2H), 6.30 (s, 1H), 7.09 (m,
6H), 7.30 (d, J= 8.0, 2H), 7.66 (d, J= 8.4, 2H), 7.77 (d, J= 8.0, 2H).
MS(ESI): m/z 551 (M+Na+).
4.1.4. 2-(1-(4-Fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)-1H-
pyrrol-3-yl)ethyl-4-methyl benzenesulfonate (14c).
The title compound was obtained starting from the hydroxyl deri-
vative 13c (0.41 g, 1.10mmol) as a white solid (0.50 g, yield 86%)
using petroleum ether-ethyl acetate (8:2 v/v) as the eluting mixture. 1H
NMR (400MHz, CDCl3) δ ppm: 2.00 (s, 3H), 2.41 (s, 3H), 2.84 (t,
J=7.1, 2H), 3.00 (s, 3H), 4.19 (t, J=7.2, 2H), 6.31 (s, 1H), 6.84 (dd,
J=9.1, 2.0, 1H), 6.90 (d, J=7.9, 1H), 7.13 (m, 3H), 7.31 (d, J=8.2,
2H), 7.36 (m, 1H), 7.67 (d, J= 8.3, 2H), 7.77 (d, J=8.2, 2H). MS(ESI):
m/z 551 (M+Na+).
4.1.5. General procedure for the synthesis of alkyl sulfides 10a-c.
To a solution of the appropriate tosyl derivative 14a-c (1
Figure 5. Crystallographic structure of compound 14b. Ellipsoids enclose 50%
probability.
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equivalent) in anhydrous DMSO (15mL), sodium 1-propanthiolate (1.5
equivalents) was added. The reaction mixture was stirred at room
temperature under nitrogen atmosphere for 1 h, then diluted with
water, and washed with ethyl acetate. The organic layer was dried over
sodium sulfate, filtered and concentred under reduce pressure. The
residue was purified by flash chromatography using petroleum ether-
ethyl acetate (7:3 v/v) as the eluting mixture.
4.1.6. 2-Methyl-5-(4-(methylsulfonyl)phenyl)-1-phenyl-3-(2-(propylthio)
ethyl)-1H-pyrrole (10a).
The title compound was obtained starting from tosyl derivative 14a
(0.30 g, 0.59mmol) as an off-white solid (0.17 g, yield 69%,
mp=107.5–108.5). 1H NMR (400MHz, CDCl3) δ ppm: 0.99 (t, J=7.2,
3H), 1.60–1.66 (m, 2H), 2.04 (s, 3H), 2.55 (t, J= 7.2, 2H), 2.75 (s, 4H),
2.96 (s, 3H), 6.43 (s, 1H), 7.12 (d, J=8.4, 4H), 7.37 (m, 3H), 7.61 (d,
J=8.4, 2H). MS(ESI): m/z 414 (M+H+).
4.1.7. 1-(4-Fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)-3-(2-
(propylthio)ethyl)-1H-pyrrole (10b).
The title compound was obtained starting from tosyl derivative 14b
(0.30 g, 0.57mmol) as a white solid (0.20 g, yield 81%,
mp=111.5–113.5 °C). 1H NMR (400MHz, CDCl3) δ ppm: 0.99 (t,
J=7.2, 3H), 1.64 (m, 2H), 2.03 (s, 3H), 2.55 (t, J= 7.2, 2H), 2.75 (s,
4H), 2.98 (s, 3H), 6.42 (s, 1H), 7.05–7.24 (m, 6H), 7.64 (d, J=8.0,
2H). MS(ESI): m/z 432 (M+H+).
4.1.8. 1-(3-Fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)-3-(2-
(propylthio)ethyl)-1H-pyrrole (10c).
The title compound was obtained starting from tosyl derivative 14c
(0.10 g, 0.19mmol) as a white solid (0.070 g, yield 85%). 1H NMR
(400MHz, CDCl3) δ ppm: 0.99 (t, J=7.4, 3H), 1.64 (m, 2H), 2.05 (s,
3H), 2.55 (t, J= 7.4, 2H), 2.74 (s, 4H), 2.98 (s, 3H), 6.42 (s, 1H), 6.87
(d, J=8.8, 1H), 6.92 (d, J=8.0, 1H), 7.09 (m, 1H), 7.14 (d, J=8.0,
2H), 7.35 (m, 1H), 7.64 (d, J=8.0, 2H). MS(ESI): m/z 432 (M+H+).
4.1.9. General procedure for the synthesis of sulfoxide (11a,b) and sulfone
derivatives (12a,b).
To a solution of the appropriate sulfide (10a,b, 1 equivalent) in
anhydrous dichloromethane (15mL), a solution of m-ClPBA (2
equivalents) in CH2Cl2 (15mL) was added slowly at 0 °C. The resulting
mixture was stirred for 2 h at room temperature under a nitrogen at-
mosphere. The reaction mixture was washed with a saturated NaHCO3
solution and then with water. The organic layer was dried over sodium
sulfate, filtered, and concentred under reduced pressure. The residue
was purified by flash chromatography using petroleum ether-ethyl
acetate (8:2) as eluent to obtain the sulfone derivative (12a,b) and then




The title compound was obtained starting from sulfide derivative
10a (0.10 g, 0.24mmol) as a white solid (0.060 g, yield 58%). 1H NMR
(400MHz, CDCl3) δ ppm: 1.08 (t, J=7.4, 3H), 1.78–1.87 (m, 2H), 2.06
(s, 3H), 2.58–2.78 (m, 2H), 2.97 (m, 7H), 6.42 (s, 1H), 7.12 (m, 4H),
7.37 (m, 3H), 7.62 (d, J=8.4, 2H). MS(ESI): m/z 430 (M+H+).
4.1.11. 1-(4-Fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)-3-(2-
(propylsulfinyl)ethyl)-1H-pyrrole (11b).
The title compound was obtained starting from sulfide derivative
10b (0.10 g, 0.23mmol) as a white solid (0.066 g, yield 62%,
mp=174.0–175.0 °C). An analytical sample was obtained by re-
crystallization from ethyl acetate by slow evaporation (Figure 6). 1H
NMR (400MHz, CDCl3) δ ppm: 1.08 (t, J=7.4, 3H), 1.80–1.92 (m,
2H), 2.05 (s, 3H), 2.60–3.11 (m, 9H), 6.42 (s, 1H), 7.03–7.14 (m, 6H),
7.64 (d, J=8.4, 2H). MS(ESI): m/z 448 (M+H+).
4.1.12. 2-Methyl-5-(4-(methylsulfonyl)phenyl)-1-phenyl-3-(2-
(propylsulfonyl)ethyl)-1H-pyrrole (12a).
The title compound was obtained as a secondary product from the
reaction mixture of compound 11a as an off-white solid (0.010 g, yield
10%). 1H NMR (400MHz, CDCl3) δ ppm: 1.06 (t, J=7.2, 3H), 1.88 (m,
2H), 2.06 (s, 3H), 2.91 (m, 2H), 2.99–3.07 (m, 5H), 3.21 (m, 2H), 6.39
(s, 1H), 7.09–7.13 (m, 4H), 7.39 (m, 3H), 7.64 (d, J=8.8, 2H). MS
(ESI): m/z 446 (M+H+).
4.1.13. 1-(4-Fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)-3-(2-
(propylsulfonyl)ethyl)-1H-pyrrole (12b).
The title compound was obtained obtained as a secondary product
from the reaction mixture of compound 11b as an off-white solid
(0.010 g, yield 9%, mp=158.5–162.0 °C). 1H NMR (400MHz, CDCl3) δ
ppm: 1.06 (t, J=7.2, 3H), 1.86 (m, 2H), 2.05 (s, 3H), 2.92 (m, 2H),
2.99–3.07 (m, 5H), 3.20 (m, 2H), 6.38 (s, 1H), 7.08–7.14 (m, 6H), 7.66
(d, J=8.4, 2H). MS(ESI): m/z 464 (M+H+).
4.2. Pharmacology. In vitro anti-inflammatory study.
The in vitro profiles of compounds 10a-c, 11a,b, and 12a,b, related
to their inhibitory activity toward both COX-1 and COX-2 isoenzymes
were evaluated through a cell-based assay employing murine mono-
cyte/macrophage J774 cell lines. The cell line was grown in DMEM
supplemented with 2mM glutamine, 25mM HEPES, 100 units/mL
penicillin, 100 μg/mL streptomycin, 10% fetal bovine serum (FBS), and
1.2% sodium pyruvate. Cells were plated in 24-well culture plates at a
density of 2.5× 105 cells/mL or in 60mm diameter culture dishes
(3×106 cells per 3mL per dish) and allowed to adhere at 37 °C in 5%
CO2 for 2 h. Immediately before the experiments, the culture medium
was replaced with fresh medium and cells were stimulated as pre-
viously described.38 The evaluation of COX-1 inhibitory activity was
achieved by pre-treating cells with the test compounds (10 μM) for
15min and then incubating them at 37 °C for 30min with 15 μM ara-
chidonic acid to activate the constitutive COX. For the compounds with
COX-1% inhibition higher than 50% (at 10 μM), the cells were also
treated with lower concentrations (0.1–1 μM). At the end of the in-
cubation, the supernatants were collected for the measurement of
prostaglandin E2 (PGE2) levels by a radioimmunoassay (RIA). To
evaluate COX-2 activity, the cells were stimulated for 24 h with Es-
cherichia coli lipopolysaccharide (LPS, 10 μg/mL) to induce COX-2, both
Figure 6. Crystallographic structure of compound 11b. Ellipsoids enclose 50%
probability.
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in the absence and in the presence of the test compounds (0.01–10 μM).
Celecoxib was used as a reference compound for the selectivity index.
The supernatants were collected for the measurement of PGE2 by
means of RIA.
4.3. In vivo anti-inflammatory and antinociceptive study.
In vivo anti-inflammatory activity of the title compounds was also
assessed and performed as follows:
4.3.1. Animals.
Male Swiss albino mice (23–25 g) and Sprague−Dawley or Wistar
rats (150–200 g) were used. Fifteen mice and four rats were housed per
cage. The cages were placed in the experimental room 24 h before the
test for acclimatization. The animals were fed with a standard labora-
tory diet and tap water ad libitum and kept at 23 ± 1 °C with a 12 h
light/dark cycle, light on at 7 a.m. All experiments were carried out in
accordance with the NIH Guide for the Care and Use of Laboratory
Animals. All efforts were made to minimize animal suffering and to
reduce the number of animals used.
4.3.2. Paw-pressure test
The paw-pressure test was performed by inducing an inflammatory
process by the intraplantar (i.pl.) carrageenan (0.1 mL, 1%) adminis-
tration 4 h before the test. The nociceptive threshold in the rat was
determined with an analgesimeter, according to the method described
by Leighton et al.39 Threshold pressure was measured before and 30, 60,
and 120min after treatment. An arbitrary cut-off value of 250 g was
adopted.
4.3.3. Carrageenan-induced edema.
The carrageenan-induced paw edema test was also performed. Rat
paw volumes were measured using a plethysmometer. Four hours after
the injection of carrageenan (0.1 mL injection of 1.0%), the paw volume
of the right hind paw was measured and compared with saline/carra-
geenan treated controls. Rats received test compounds 3 h 30min after
carrageenan. The results are reported as paw volume expressed in mL.
4.3.4. Antinociceptive assay.
Antinociceptive activity was determined by means of an in-
traperitoneal (i.p.) injection of a 0.6% acetic acid (10mL/kg) induced
writhing in the mouse abdominal constriction test according to
Koster.40 The number of stretching movements was counted for 10min,
starting 5min after acetic acid injection.
4.4. Analysis of in vitro metabolic stability of 10a and 10b in human liver
microsomes
Compounds 10a and 10b, dissolved in ACN, was incubated at 37 °C,
separately at 10 μM concentration in 100mM phosphate buffer (pH 7.4)
with 0.48mg/mL human as previously reported.41 Enzymatic reactions
were started by addition of a NADPH-regenerating system (2mM
NADPH), 10mM glucose-6-phosphate, 0.4 U/ml glucose-6-phosphate
dehydrogenase). Reactions were terminated at regular time intervals
(overall range 0–60min) by adding a double volume of acetonitrile. All
incubations were performed in triplicate. HPLC analysis was performed
on Agilent 1100 Series liquid chromatography system equipped with a
Merck LiChroCART® 250–4,6 and coupling with UV–VIS detector, set-
ting at λ 234 nm. Analysis was carried out using gradient elution of a
binary solution; eluent A was ACN (acetonitrile), while eluent B con-
sisting of an aqueous solution of formic acid (0.1%). The analysis
started at 0% A for three minutes, then rapidly increased up to 98% in
12min and finally remaining at 98% A until 18min. The analysis was
performed at flow rate of 0.8mLmin−1 and injection volume was
20 µL. The intrinsic clearance (Clint) was calculated by the equation:
=Clint k(min )x[V]/[P]1
where k is the rate constant for the depletion of substrate, V is the
volume of incubation in μL and P is the amount of microsomal proteins
as reported elsewhere.42
4.5. Computational details
4.5.1. Ligands and protein preparation
The hCOX-2 crystal structure (PDB ID: 5KIR)43 was taken from
protein data bank and prepared by Protein Preparation Wizard (PPW)
protocol (Maestro suite 2011) for obtaining suitable structures for
molecular docking calculations as previously reported.44,45 Water mo-
lecules and compounds used in the crystallization process were re-
moved. PPW protocol performed a series of computational steps to: (1)
add hydrogens, (2) optimize the orientation of hydroxyl groups, Asn,
and Gln, and the protonation state of His, and (3) perform a constrained
minimization refinement with the impref utility. The refined proteins
were used in molecular docking calculation as reported in the next
paragraph. The 3D structures of ligands were built in Maestro 9.2
(Schrödinger, LLC, New York, NY, 2011). MacroModel software was
used for the energy minimizations employing the OPLS-2005 force
field. The solvent effects were simulated using the analytical General-
ized-Born/Surface-Area (GB/SA) model46 and no cut-off for nonbonded
interactions was selected. Polak-Ribiere conjugate gradient (PRCG)
method with 1000 maximum iterations and 0.001 gradient convergence
threshold was employed. All compounds reported in this paper were
treated by LigPrep application (LigPrep version 2.5, Schrödinger, LLC,
New York, NY, 2011) in order to generate the most probable ionization
state at cellular pH (7.4 ± 0.2) as reported by us.47–49
4.5.2. Molecular docking
Glide software (Glide, version 5.7, Schrödinger, LLC, New York, NY,
2011) has been employed to perform the docking studies presented in
this paper, using the ligands and proteins prepared as above-mentioned,
applying Glide extra precision (XP) scoring function.50,51 Energy grids
were prepared using default value of protein atom scaling factor (1.0 Å)
within a cubic box centered on the crystallized ligand (Rofecoxib). After
grid generation, the ligands were docked into the enzymes. The number
of poses entered to post-docking minimization was set to 50. Glide XP
score was evaluated. In order to assess the validity of docking protocol,
compounds crystallized with hCOX-2 were used as reference com-
pounds (rofecoxib from 5KIR,43 salicylic acid from 5F1A,52 meclofe-
namic acid from 5IKQ,53 mefenamic acid from 5IKR,53 tolfenamic acid
from 5IKT,53 and flufenamic acid from 5IKV53) for a re-docking pro-
cedure. The docking results revealed a similar accommodation for the
above mentioned reference compounds with respect to the crystal
structures with low RMSD (data not shown).
4.5.3. P450 site of metabolism
Compounds 10a and 10b were evaluated for their potential sites of
metabolism by P450 site of metabolism (P450 SOM) workflow (P450
Site of Metabolism Prediction, version 1.1, Schrödinger, LLC, New York,
NY, 2011) implemented in Schrödinger suite 2011.35 For each molecule
P450 SOM performed a calculation of intrinsic reactivity coupled to
induced-fit docking (IFD) (Schrödinger Suite 2011; Induced Fit Docking
protocol; Glide version 5.7, Schrödinger, LLC, New York, NY, 2011;
Prime version 3.0, Schrödinger, LLC, New York, NY, 2011) for the se-
lected isoform of cytochrome. The reactivity rules have been para-
meterized in P450 SOM to predict atomic reactivity profiles for pro-
miscuous P450 enzymes that are thought to be mostly independent of
structural restrictions on the binding poses. The reactivity is predicted
with a linear free energy approach based on the Hammett and Taft
scheme, where the reactivity of a given atom is the sum of a baseline
reactivity rate and a series of perturbations determined by the con-
nectivity.37 The induced-fit docking approach is a variation on the
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normal protocol. The initial sampling is enhanced by generating mul-
tiple starting conformations, so that a wider range of poses is found in
the initial docking stage. The initial docking includes van der Waals
scaling of the receptor and alanine mutation of the most flexible re-
sidues. In the Prime refinement step, any residue with an atom within
5 Å of any ligand pose is selected for side-chain prediction. The sub-
sequent minimization includes the ligand, side chains, and backbones of
the flexible residues. The ligand is then redocked into each of the low-
energy protein conformations, determined by a 40 kcal/mol cut-off.
There is no final scoring stage, because all poses are considered in de-
termining which atoms are sufficiently accessible to the reactive heme
iron. Any atom within the cut-off distance of 5 Å from the heme iron is
considered as a potential site of metabolism.37
4.6. X-Ray crystallography
Single crystals of 11b and 14b were submitted to X-ray data col-
lection on an Oxford-Diffraction Xcalibur Sapphire 3 (Santa Clara, CA,
USA) diffractometer with a graphite monochromated Mo-Kα radiation
(λ=0.71073 Å) at 293 K. The structures were solved by direct methods
implemented in SHELXS-2013 program.54 The refinements were carried
out by full-matrix anisotropic least-squares on F2 for all reflections for
non-H atoms by means of the SHELXL-2018 program.55 Crystal-
lographic data (excluding structure factors) for the structure in this
paper have been deposited with the Cambridge Crystallographic Data
Centre as supplementary publications no. CCDC 1,881,112 (11b), and
1,881,113 (14b). Copies of the data can be obtained, free of charge, on
application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK; (fax:
+44(0)-1223–336-033; or e-mail: deposit@ccdc.cam.ac.uk).
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